Rituximab and Belimumab for Lupus Nephritis

ClinicalTrials.gov ID: NCT02260934

Public ClinicalTrials.gov record NCT02260934. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

In this experimental study, researchers will try to find out if treatment of lupus nephritis with a combination of rituximab and cyclophosphamide (CTX), or a combination of rituximab and CTX followed by treatment with belimumab is safe and if this drug combination can block the immune system attacks.

Study identification

NCT ID: NCT02260934
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Enrollment: 43 participants

Conditions and interventions

Conditions

Lupus Nephritis

Interventions

Biological · Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 9, 2015 (Actual)
Primary completion: Mar 12, 2018 (Actual)
Completion: Feb 8, 2019 (Actual)
Last update posted: Dec 1, 2020

2015 – 2019

United States locations

U.S. sites: 15
U.S. states: 10
U.S. cities: 13

Facility	City	State	ZIP	Site status
University of Alabama, Birmingham	Birmingham	Alabama	35294	—
UCLA Medical Center: Division of Rheumatology	Los Angeles	California	90095	—
University of California, San Francisco	San Francisco	California	94143	—
University of Colorado Denver: School of Medicine: Division of Rheumatology	Aurora	Colorado	80045	—
Colorado Kidney Care	Denver	Colorado	80218	—
Emory University School of Medicine	Atlanta	Georgia	30303	—
Washington University in St. Louis	St Louis	Missouri	36110	—
Feinstein Institute, North Shore Hospital	Manhasset	New York	10030	—
New York University, Langone Medical Center	New York	New York	10016	—
Weill Cornell Medical College: Hospital for Special Surgery -	New York	New York	10021	—
Columbia University Medical Center	New York	New York	10032	—
University of North Carolina School of Medicine:	Chapel Hill	North Carolina	27599	—
Ohio State University Wexner Medical Center:	Columbus	Ohio	43213	—
Medical University of South Carolina	Charleston	South Carolina	29425	—
University of Texas Southwestern	Dallas	Texas	75390	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02260934, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 1, 2020 · Synced Oct 18, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02260934 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →